T-cell therapy |
Primary BALB/c mouse T-cells | BALB/c mouse | N/A | BODIPy-TR PFPE | Intraperitoneal | 2 | T cell homing to the abdominal LN | [22] |
Human CAR T against EGFRvIII | SCID mouse | glioblastoma SC | CS-1000 ATM | Intravenously | 2, 7, 14 | CAR T cell homing to the tumors and spleen, reduced tumor growth | [40] |
DO11.10 mouse T cells | BALB/c mouse | chicken ova SC | PFPE/PFPE –Alexa657 | Intraperitoneal | 4, 7, 11, 21 | T cell homing to the draining inguinal LN and persistence over 3 weeks | [35] |
Naïve T cells, OT-1 T cells | C57BL/6 mouse | melanoma expressing ova | CS-1000 ATM | Intravenously | 1 | No signal found in the tumor, but found in the chest (lungs), abdomen (liver), and left flank (spleen) | [41] |
Pmel-1 cytotoxic T cells | C57BL/6 mouse | CNS glioma | PCE | Intravenously | 3, 5, 7, 12 | Significant pO2 increase in Pmel-1 treated mice at day 5 compared to controls | [71] |
NK cell therapy |
Human NK cells | NSG mouse | neuroblastoma SC | CS-1000 ATM | Subcutaneously or intratumorally | 1, 3, 7/8, 10, 15 | NK cell detection and persistence at injection sites, no evidence of migration | [37] |
Human NK cells | NSG mouse | meduloblastoma CNS | CS-ATM DM Green | Intratumorally | 0 | In vivo visualization of NK cells after transfer | [36] |
DC vaccines |
Mouse bone marrow-derived DC | C57BL/6 mouse | N/A | PCE | Intradermally in the limb | 1 | Migration of antigen-loaded DC from the footpad to the draining lymph node | [32] |
In situ DC labeling | C57BL/6 mouse | CNS glioma | Rhodamine-PCE | Intravenously | 1 | Migration if In situ labeled DC to CNS tumors, reduced tumor growth | [59] |
Mouse bone marrow-derived DC | C57BL/6 mouse | N/A | Rhodamine-PCE | Intradermally in the limb | 0 | Migration of Erk−/− DC to the draining popliteal lymph node | [59] |
Autologous human DC vaccine* | Human | Metastatic colorectal cancer | CS-1000 (PFPE) | Intradermally in quadriceps | 0, 1 | Succesful first-in-man detection of DC vaccine in patients | [14] |
PBMCs |
Human PBMC | Nude mouse, ham shank | N/A | CS-1000 ATM | Intradermally and Intramuscularly | 0, 2 | Clinical protocol implementation for detection of PBMC in skin and muscle at 1.2 cm depth | [61] |